Ophthalmic Drugs Market Forecast 2015-2025: Prospects for Leading Companies in Dry Eye, Glaucoma, Retinal Disorders, Allergic, Inflammatory & Infective Drugs

LONDON, July 24, 2015 /PRNewswire/ --

Ophthalmic drugs - new study showing you trends, partnerships, and predicted revenues
Where is the market for ophthalmic drugs heading? What are the commercial prospects for this market? Visiongain's new report shows you potential revenues and other trends to 2025, discussing data, opportunities and prospects.

Our 337 page report provides 243 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess:
• Forecasted sales at world market, submarket, regional and national level
• You will see financial results and revenue predictions
• Interviews, trends, opportunities

Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. There you will find:
• Original analyses, with business outlooks and developments
• Discover qualitative analyses (including SWOT and Porter's Five Forces)
• Company profiles and commercial developments

Read the full transcript of three exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
• Dr Patrik De Haes, CEO, ThromboGenics nv
• Mr Wouter Piepers, Global Head of Corporate Communications & Investor Relations, ThromboGenics nv
• A spokesperson for Akorn Pharmaceuticals

You will find prospects for key submarkets
In addition to analyses of the overall world market, you will see revenue forecasting of five world-level submarkets to 2025:
• Glaucoma drugs market forecast 2015-2025
• Dry eye drugs market forecast 2015-2025
• Allergic, inflammatory and infective drugs market forecast 2015-2025
• Retinal disorder drugs market forecast 2015-2025
• Other ophthalmic drugs market forecast 2015-2025

To see a report overview please email Sara Peerun on [email protected]

Our investigation shows business research and analysis with individual revenue forecasts and discussions for each submarket.

See revenue forecasts for products
How will leading drugs perform to 2025 at world level? Our study forecasts sales of 27 marketed drugs, including these brands:
• Lucentis
• Eylea
• Restasis
• Vigamox
• Pataday/ Patanol
• Jetrea
• Lumigan and Ganfort
• Xalatan/Xalacom
• Zioptan
• Cravit

Discover how high revenues can go. You will see what's happening, understanding trends, challenges and opportunities.

What are the prospects for the leading regions and countries?
You will discover individual revenue forecasts for 12 leading national markets to 2025. There are many commercial opportunities to exploit in both developed and developing countries.
• US
• China
• Japan
• Germany
• India
• France
• UK
• Italy
• Spain
• Brazil
• Russia
• Mexico
• Rest of the World

Our analyses show that emerging economies, particularly in South America and Asia, will continue to achieve high revenue growth to 2025. Various economic, geographical, and regulatory factors globally will influence the market.

Leading companies and potential for market growth
We expect the rising demand for ophthalmic drugs, expanding healthcare coverage, the strength of the R&D pipeline and developments in drug delivery technologies to contribute to a significant increase in sales for ophthalmic drugs to 2025.

To see a report overview please email Sara Peerun on [email protected]

Our work shows you what organisations hold greatest potential. See profiles of 9 leading companies, including these:
• Pfizer
• Santen
• Bayer
• Senju
• Regeneron
• Novartis (Alcon)
• Allergan (Actavis)
• Roche
• Valeant (including Bausch & Lomb)

A company profile gives you the following information:
• Revenue forecast for ophthalmic drugs from 2015 to 2025
• Recent financial results
• Assessment of recent developments - mergers and acquisitions (M&A), and collaborations, including alliances, partnerships, and joint ventures
• Discussion of a company's activities and outlook
• Ophthalmic drugs revenue forecast from 2015 to 2025

Discover capabilities, progress, and commercial prospects, helping you stay ahead. What effects will regulatory changes have?

Research and development activities - assess innovation, trends and possibilities
What is happening in the R&D pipeline for ophthalmic treatments? You see developmental trends, gaining insight into each phase of the ophthalmology R&D pipeline for:
• Dry eye drugs
• Glaucoma drugs
• Allergic, infective and inflammatory drugs
• Retinal disorder drugs
• Other progress in ophthalmology

Our study also discusses these agents and technologies, among others:
• Gene therapy
• Oral drug candidates
• Drug delivery
• Novel small molecules

What issues will affect the ophthalmic drugs market?
Our new report lets you assess industry trends and outlooks. Our study discusses issues affecting ophthalmic treatments. You will find discussions, including qualitative analyses:
• A strong R&D pipeline
• Patent expiries and generic competition
• Patient compliance and the advances in topical drug delivery
• Pricing and reimbursement pressures created by government cost-cutting initiatives
• Growth areas in dry eye and retinal disorders
• The changing socio-economic conditions impacting ophthalmic drug demand

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape

How the Ophthalmic Drugs Market Forecast 2015-2025: Prospects for Leading Companies in Dry Eye, Glaucoma, Retinal Disorders, Allergic, Inflammatory & Infective Drugs report helps you
In summary our 337 page report gives you the following knowledge:
• Revenues to 2025 for the overall ophthalmic drugs market - discover the industry's prospects, finding promising areas for investments and revenues
• Revenue forecasts to 2025 for four product categories (therapeutic classes) within ophthalmic drugs - discover forecasts for Dry eye drugs, Retinal disorders drugs, Glaucoma drugs, Allergic, inflammatory and infective drugs, and Other ophthalmic drugs
• Revenue forecast to 2025 for 12 leading national markets - US, China, Japan, India, Germany, France, UK, Italy, Spain, Russia, Brazil, Mexico, and Rest of the World
• Assess leading companies - hear about the products, results and strategies, including recent activities, future outlook, and ophthalmic drugs revenue forecast for 9 leading companies, including Pfizer, Novartis, Roche, Regeneron, Senju, Bayer, Santen, Valeant, and Allergan
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
• Opinions from our survey, seeing interviews with industry authorities
• IP protection and generic drug competition - see what affects product revenue

You will find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the ophthalmic drugs market and the leading companies within it. You will find data, trends and predictions. Please order our report now.

Companies Mentioned in the Report
Abbott
Actavis
Acucela
Advanced Cell Technologies
Aerie Pharmaceuticals
Aerpio Therapeutics
Akorn Pharmaceuticals
Alcon (Novartis)
Aldeyra Therapeutics
Alimera Sciences
Allegro Ophthalmics
Allergan
Amakem
Amgen
Ampio Pharmaceuticals
AstraZeneca
Banyu Pharmaceutical
Barr Laboratories
Bausch and Lomb
Bayer
Bicycle Therapeutics
Biocad
BioDem
Biovail Corporation (Valeant)
BioXpress Therapeutics
Bristol-Myers Squibb
Can-Fite BioPharma
Chengdu Kanghong Pharmaceutical
Colby Pharmaceutical
Daiichi Sankyo
Delenex Therapeutics
Eleven Biotherapeutics
ESBA Tech
EyeCyte
EyeGate
Eyetech Pharmaceuticals
ForSight Biotherapeutics
Genaera Corporation
Gene Signal
Genentech (Roche)
GlaxoSmithKline
High-Tech Pharmacal
Hospira (Pfizer)
iCo Therapeutics
Icon Bioscience
InSite Vision
Inspire Pharmaceuticals (Merck)
Instituto Terapeutico Delta Ltda (Valeant)
ISTA Pharmaceuticals
Johnson & Johnson
Kala Pharmaceuticals
KalVista
Kestrel Ophthalmics
Kyowa Hakko Kirin
LEO Pharma
Lpath
MacuCLEAR
MAP Pharmaceuticals
Meda Pharmaceuticals
Merck & Co
MerLion Pharma
Mimetogen Pharma
Molecular Partners AG
Morgan Stanley
Mystic Pharmaceuticals
Neurim Pharmaceuticals
Neurotech
NovaBay
Novartis
OcuSciences
OHR Pharmaceutical
Omeros
Oncobiologics
OphthaliX
Ophthotech
Othera Pharmaceuticals
Oxigene
Pan Optica
Patheon Pharmaceuticals
Pershing Square Capital
Pfizer
Premacure (Shire)
Procter & Gamble
pSivida
QLT
Quark Pharmaceuticals
Reckitt Benckiser
Regeneron
Roche
R-Tech Ueno
Salix Pharmaceuticals (Valeant)
Sandoz (Novartis)
Santen
SARcode Bioscience
Seikagaku
Senju
Servier
Shire
Sirna Therapeutics
Spark Therapeutics
Swedish Orphan Biovitrium AB (Sobi)
Symphony VIDA
Takeda
The Patent Board
ThromboGenics
Valeant
Vanda Pharmaceuticals
Warburg Pincus LLC
Wockhardt
Zhejiang Huahai Pharmaceutical

Organisations Mentioned in the Report
American Academy of Ophthalmology (AAO)
American Diabetes Association
American Society of Retina Specialists (ASRS)
Association for Research in Vision and Ophthalmology (ARVO)
Department of Pharmaceuticals [India]
Emory University, Georgia, US
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Medicines Agency (EMA)
Food and Drug Administration (FDA) [US]
Foundation Fighting Blindness (FFB)
Institute of Experimental Medicine, St Petersburg, Russia
International Diabetes Federation
Italian Competition Authority
Italian Medicines Agency (AIFA)
Japan Patent Office
Memorial Sloan Kettering Cancer Center, New York, US
Ministry of Health, Labour and Welfare (MHLW) [Japan]
Monash University, Australia
National Development and Reform Commission [China]
National Eye Institute [US]
National Institute for Health and Care Excellence (NICE) [UK]
National Pharmaceutical Pricing Authority (NPPA) [India]
Novartis Institutes for Biomedical Research (NIBR)
Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
Portsmouth Primary Care Trust [UK]
Southampton Primary Care Trust [UK]
Tokyo University of Science
United Nations' Department of Economic and Social Affairs
University of Florida, US
University of Melbourne, Australia
US Patent and Trademark Office
US Preventive Services Task Force (UPSTF)
World Bank
World Health Organisation (WHO)

To see a report overview please email Sara Peerun on [email protected]

To request an exec summary of this report please email Sara Peerun at [email protected]

or call Tel: +44-(0)20-7336-6100

Or click on https://goo.gl/RMBnwy

SOURCE Visiongain